Renalytix RTNXF Stock
Renalytix Price Chart
Renalytix RTNXF Financial and Trading Overview
| Renalytix stock price | 0.08 USD |
| Previous Close | 1.01 USD |
| Open | 1.01 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.01 - 1.01 USD |
| 52 Week Range | 0.75 - 1.96 USD |
| Volume | 2K USD |
| Avg. Volume | 146 USD |
| Market Cap | 97.53M USD |
| Beta (5Y Monthly) | 1.9585 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RTNXF Valuation Measures
| Enterprise Value | 73.32M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 26.246683 |
| Price/Book (mrq) | 5.2331605 |
| Enterprise Value/Revenue | 19.73 |
| Enterprise Value/EBITDA | -1.63 |
Trading Information
Renalytix Stock Price History
| Beta (5Y Monthly) | 1.9585 |
| 52-Week Change | -48.46% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.96 USD |
| 52 Week Low | 0.75 USD |
| 50-Day Moving Average | 1.57 USD |
| 200-Day Moving Average | 1.37 USD |
RTNXF Share Statistics
| Avg. Volume (3 month) | 146 USD |
| Avg. Daily Volume (10-Days) | 200 USD |
| Shares Outstanding | 93.78M |
| Float | 69.66M |
| Short Ratio | N/A |
| % Held by Insiders | 43.77% |
| % Held by Institutions | 9.92% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1219.26% |
| Gross Margin | 27.28% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -67.20% |
| Return on Equity (ttm) | -166.93% |
Income Statement
| Revenue (ttm) | 3.72M USD |
| Revenue Per Share (ttm) | 0.05 USD |
| Quarterly Revenue Growth (yoy) | -10.80% |
| Gross Profit (ttm) | 874K USD |
| EBITDA | -44985000 USD |
| Net Income Avi to Common (ttm) | -39656000 USD |
| Diluted EPS (ttm) | -0.7 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 33.03M USD |
| Total Cash Per Share (mrq) | 0.35 USD |
| Total Debt (mrq) | 11.62M USD |
| Total Debt/Equity (mrq) | 64.23 USD |
| Current Ratio (mrq) | 2.433 |
| Book Value Per Share (mrq) | 0.193 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -39619000 USD |
| Levered Free Cash Flow (ttm) | -26369500 USD |
Profile of Renalytix
| Country | United States |
| State | NY |
| City | New York |
| Address | 1460 Broadway |
| ZIP | 10036 |
| Phone | 646 397 3970 |
| Website | https://renalytix.com |
| Industry | Health Information Services |
| Sector(s) | Healthcare |
| Full Time Employees | 102 |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Q&A For Renalytix Stock
What is a current RTNXF stock price?
Renalytix RTNXF stock price today per share is 0.08 USD.
How to purchase Renalytix stock?
You can buy RTNXF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Renalytix?
The stock symbol or ticker of Renalytix is RTNXF.
Which industry does the Renalytix company belong to?
The Renalytix industry is Health Information Services.
How many shares does Renalytix have in circulation?
The max supply of Renalytix shares is 586.25M.
What is Renalytix Price to Earnings Ratio (PE Ratio)?
Renalytix PE Ratio is 0.00000000 now.
What was Renalytix earnings per share over the trailing 12 months (TTM)?
Renalytix EPS is 0 USD over the trailing 12 months.
Which sector does the Renalytix company belong to?
The Renalytix sector is Healthcare.